PT2822947T - Sais de arginina de um agonista de tlr7 - Google Patents

Sais de arginina de um agonista de tlr7

Info

Publication number
PT2822947T
PT2822947T PT137081428T PT13708142T PT2822947T PT 2822947 T PT2822947 T PT 2822947T PT 137081428 T PT137081428 T PT 137081428T PT 13708142 T PT13708142 T PT 13708142T PT 2822947 T PT2822947 T PT 2822947T
Authority
PT
Portugal
Prior art keywords
tlr7 agonist
arginine salts
arginine
salts
tlr7
Prior art date
Application number
PT137081428T
Other languages
English (en)
Portuguese (pt)
Inventor
Kay Dodd Stephanie
Jain Siddartha
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PT2822947T publication Critical patent/PT2822947T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT137081428T 2012-03-07 2013-03-07 Sais de arginina de um agonista de tlr7 PT2822947T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
PT2822947T true PT2822947T (pt) 2016-09-26

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137081428T PT2822947T (pt) 2012-03-07 2013-03-07 Sais de arginina de um agonista de tlr7

Country Status (18)

Country Link
US (1) US9320748B2 (enExample)
EP (1) EP2822947B1 (enExample)
JP (1) JP6325986B2 (enExample)
CN (1) CN104203946B (enExample)
AU (1) AU2013229466A1 (enExample)
CA (1) CA2865759C (enExample)
CY (1) CY1118091T1 (enExample)
DK (1) DK2822947T3 (enExample)
ES (1) ES2597755T3 (enExample)
HR (1) HRP20161354T1 (enExample)
HU (1) HUE030175T2 (enExample)
LT (1) LT2822947T (enExample)
MX (1) MX346678B (enExample)
PL (1) PL2822947T3 (enExample)
PT (1) PT2822947T (enExample)
RU (1) RU2014140336A (enExample)
SI (1) SI2822947T1 (enExample)
WO (1) WO2013131985A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
MX377794B (es) 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
AU2006259858A1 (en) 2005-05-12 2006-12-28 Novartis Vaccines And Diagnostics S.R.L. Immunogenic compositions for Chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007110700A2 (en) 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
ES2531115T3 (es) 2009-06-01 2015-03-10 Novartis Ag Combinaciones de clados de RrgB neumocócicos
CA2765112A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
US9950062B2 (en) * 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
SG11201400210RA (en) * 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Also Published As

Publication number Publication date
EP2822947B1 (en) 2016-08-03
JP6325986B2 (ja) 2018-05-16
CA2865759A1 (en) 2013-09-12
LT2822947T (lt) 2016-10-10
DK2822947T3 (en) 2016-09-19
MX346678B (es) 2017-03-29
HRP20161354T1 (hr) 2016-12-02
JP2015511957A (ja) 2015-04-23
CA2865759C (en) 2020-07-21
HUE030175T2 (en) 2017-04-28
AU2013229466A1 (en) 2014-09-04
EP2822947A1 (en) 2015-01-14
US9320748B2 (en) 2016-04-26
SI2822947T1 (sl) 2016-10-28
US20150125475A1 (en) 2015-05-07
RU2014140336A (ru) 2016-04-27
CY1118091T1 (el) 2017-06-28
CN104203946B (zh) 2017-03-22
CN104203946A (zh) 2014-12-10
PL2822947T3 (pl) 2017-01-31
WO2013131985A1 (en) 2013-09-12
MX2014010423A (es) 2014-09-22
ES2597755T3 (es) 2017-01-20

Similar Documents

Publication Publication Date Title
ZA201401884B (en) New dihydroquinoline-2-one derivatives
SI2822947T1 (sl) Argininske soli TLR7 agonista
EP2970081A4 (en) SALTS OF TREPROSTINIL
GB201304499D0 (en) Carcainium Salts
SG11201401937YA (en) New aryl-quinoline derivatives
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
ZA201308401B (en) Substituted benzamide derivatives
PT2838883T (pt) Novos derivados de fenil-tetra-hidroisoquinolina
ZA201409327B (en) Solid forms of a pyrido-pyrimidinium inner salt
IL231269B (en) Preparations for the treatment of HIV
ZA201406238B (en) Crystalline form of a succinate salt
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
IL237382A0 (en) Salts of a benzothiazolone compound as beta-2 adrenergic receptor agonists
PL2760822T3 (pl) Sole desfezoterodyny
GB201219868D0 (en) Facilitating completion of a form
ZA201308872B (en) Use of a dinitromethane salt
GB201100332D0 (en) Monty Izofit
ZA201205358B (en) Use of a salt of bistetrazolylamine
GB201106819D0 (en) Novel salts
GB201209895D0 (en) Use of a composition
GB201204590D0 (en) Prodrugs of thiazolamine compounds